What You Should Know:
- Community Direct DX (CDx), Scienetix, and the R&D division of Advanta Genetics have merged to form OSPRI, a new biotechnology company specializing in polymerase chain reaction (PCR)-based infectious disease detection.
- The merger creates one of the world's first fully vertically-integrated molecular testing platforms.
Addressing Cost and Complexity in PCR Testing
OSPRI will develop and deliver advanced tools to improve access to high-quality
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Ryght AI Announces Partnership with Biorasi to Transform Feasibility Accuracy in Clinical Trials
What You Should Know:
- Ryght AI, an AI clinical trial developer, today announced a partnership with Biorasi, a global clinical research organization (CRO) specializing in dermatology, oncology, neurology, and nephrology studies.
- The collaboration will bring advanced, AI-driven feasibility capabilities to biotech and biopharma sponsors.
Redefine Clinical Trial Feasibility with AI Digital Twin Technology
Ryght AI is reshaping clinical research through a next-generation platform
Read More
FemTech: Gameto Secures $44M to Advance Stem Cell Therapy for Infertility and Menopause
What You Should Know:
- Gameto, a clinical-stage biotechnology company focused on reproductive health secures $44M in Series C funding, bringing its total capital raised to a leading $127M.
- The funding, led by Overwater Ventures with participation from multiple investors including Insight Partners and RA Capital, will support the completion of the ongoing Phase 3 trial for its lead program, Fertilo.
Fertilo: A Paradigm Shift in IVF
Fertilo is a novel therapy designed to
Read More
Garden Launches BLOOM to Make AI Drug Design IP-Aware in Real Time
What You Should Know:
- Garden has announced the launch of BLOOM (Branching Lookup Optimized for Organic Molecules), a Markush structure search engine designed to give AI drug-design teams near-instant verification of small-molecule intellectual property (IP) landscapes.
- As AI models accelerate the pace of molecule generation, the critical bottleneck has shifted from discovery to due diligence—ensuring that a new candidate isn't already patented. BLOOM eliminates this bottleneck,
Read More
New Vivalink Survey Finds Nearly 90% of Americans Open to Remote Clinical Trials
What You Should Know:
- A new survey shows that remote clinical trials are not just a convenient option but a key factor in whether people choose to participate in research at all.
- The survey, conducted by digital healthcare solutions provider Vivalink, found that nearly 90% of Americans are open to participating in fully remote trials, signaling a major shift in patient expectations.
A Clear Preference for Virtual Trials
The survey, which polled over 200 U.S. adults,
Read More
M&A: Evident to Acquire Digital Pathology Solution Pramana
What You Should Know:
- Evident, a leader in clinical microscopy and superior optics, today announced a definitive agreement to acquire Pramana, Inc., a manufacturer of digital pathology solutions. Financial details of the acquisition were not disclosed.
- The strategic acquisition brings together Pramana’s cutting-edge autonomous whole slide imaging technologies with Evident’s longstanding expertise to revolutionize the market for digital pathology solutions and usher in what both
Read More
Why MedTech Needs Regulatory Intelligence, Not Just Regulatory Updates
In the past five years, medical device companies have faced continuous change, with new regulations, evolving standards, and increasing documentation requirements. The 2024 MTI Regulatory Report put it plainly: “time and bandwidth” have now overtaken cost as the biggest challenge for regulatory affairs teams.
This shift points to a deeper issue. The volume and pace of regulatory change have outgrown traditional compliance approaches. Tracking updates and reacting as they come is no longer
Read More
How Sensor Technology Is Transforming Clinical Trials
Clinical trials are the foundation of drug development, generating life-saving medicines for the betterment of society. But trials can be arduous, lengthy, and expensive for patients, sites, and sponsors, particularly in neurological disease trials, where phase III trials cost up to $370 million, last 7.9 years, and face a 95% failure rate among drug candidates 1,2,3. Moreover, traditional site-based data collection methods do not capture the complete picture of how patients are affected by
Read More
Healthcare Investment Shifts in 1H 2025: AI Remains a Bright Spot Amidst Fundraising Decline
What You Should Know:
- After a strong start to the year, the digital health sector experienced a significant pullback in Q2 2025, with deal volume declining to its lowest quarterly activity level in the last five years, according to the latest report from Silicon Valley Bank (SVB).
- The report, Mid-Year Healthcare Investment and Exits Report reveals growing investor selectivity and capital concentration in fewer, high-conviction bets amidst ongoing global economic
Read More
Briya Launches AIRE™: The World’s First Clinical-Grade AI Research Assistant to Accelerate Biomedical Discovery
What You Should Know:
- Briya, a health technology company redefining medical research launches Briya AIRE™, the world's first clinical-grade AI research assistant built to accelerate biomedical and clinical decision-making.
- Designed to "think" in the language of medicine, clinical research, and epidemiology, AIRE aims to transform months of manual data analysis into actionable insights in minutes, enabling faster, cost-effective discovery across biopharma and academic research
Read More
